SEC Form 4 · accession 0001756253-26-000009
Jazz Pharmaceuticals plc · JAZZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Douglas Smith
Director
Period of report
Aug 31, 2026
Accepted (ET)
Sep 2, 2026 · 5:34 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001232524
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Aug 31, 2026 | F | 14 | $244.6443 | D | 11,271 | D | |
| Ordinary Shares | Aug 31, 2026 | F | 1,692 | $241.39 | D | 9,579 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.